Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-12-13 21:45 CET (UTC+1h)
 

calculation of 90% CI for continuous variable in clinical endpoint studies [General Sta­tis­tics]

posted by GM - India, 2017-11-17 04:55  - Posting: # 17986
Views: 694

(edited by GM on 2017-11-17 05:07)

Hello All,

As I am new to the endpoint studies, how can we calculate 90% CI for continuous variable in clinical endpoint studies?

As per my understanding, there are two ways. One is ±20 rule for the difference of means and 80-120% rule for ratio of means of un-transformed data. Based on this reference 90% CI Calculation

But as per OGD, the 90%CI should lies in 80-125% for un-transformed data. Please see the point no.21 in the OGD (see Clindamycin Phosphate).

This is :confused: me a lot. Please clarify.


Edit: URL corrected. Please don’t link to a Google-India search term. [Helmut]

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,558 Posts in 3,759 Threads, 1,090 registered users;
27 users online (0 registered, 27 guests).

The purpose of models is not to fit the data,
but to sharpen the questions.    Samuel Karlin

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed